# Funds Received from Participating Corporations for Fiscal Year 2026

***In fiscal year 2026, ACNP had a total of $17,489,011 in revenue from the following sources:***



**All funds from pharmaceutical companies are listed below.**

***Participating Corporations Fees***

| | | |
|---|---|---|
| Acadia Pharmaceuticals | $25,000.00 | |
| Alkermes | $25,000.00 | |
| Abbvie (formerly Allergan) | $75,000.00 | |
| Alto Neuroscience | $6,000.00 | |
| Arrivo Bio | $12,500.00 | |
| Axsome Therapeutics | $25,000.00 | |
| Autobahn Therapeutics | $6,000.00 | |
| Beacon Biosignals | $6,000.00 | |
| Biogen | $25,000.00 | |
| Boehringer Ingelheim | $75,000.00 | |
| Bristol-Myers | $75,000.00 | |
| CenExel | $16,500.00 | |
| Clinilabs | $6,000.00 | |
| COMPASS Pathways | $12,500.00 | |
| Cybin | $12,500.00 | |
| Delix Therapeutics | $6,000.00 | |
| EMA Wellness LLC | $6,000.00 | |
| Eisai Inc. | $12,500.00 | |
| Engrail Therapeutics | $6,000.00 | |
| Evolution Research Group | $6,000.00 | |
| Gilgamesh Pharmaceuticals | $6,000.00 | |
| Intra-Cellular Therapies, Inc. | $12,500.00 | |
| IQVIA | $6,000.00 | |
| Janssen/JNJ | $25,000.00 | |
| LB Pharmaceuticals | $25,000.00 | |
| Magnus Medical | $6,000.00 | |
| Maplight Therapeutics | $25,000.00 | |
| Mind Medicine Inc | $12,500.00 | |
| Neumora Therapeutics | $25,000.00 | |
| Neurocrine Biosciences, Inc. | $75,000.00 | |
| Osmind | $6,000.00 | |
| Otsuka (OPDC) | $25,000.00 | |
| Reunion Neuroscience | $6,000.00 | |
| Sage Therapeutics, Inc. | $25,000.00 | |
| Signant Health (Bracket Global) | $12,500.00 | $744,500.00 |
| Transcend Therapeutics | $12,500.00 | |

# Educational Grants

| Company | Program Supported | Amount |
|---|---|---|
| N/A | N/A | N/A |